Mathew A, Cheng H M, Sam C K, Joab I, Prasad U, Cochet C
Nasopharyngeal Carcinoma Research Laboratory, University Malaya, Kuala Lumpur.
Cancer Immunol Immunother. 1994 Jan;38(1):68-70. doi: 10.1007/BF01517172.
The BamHI Z EBV replication activator (ZEBRA) protein is involved in the switch from latency to productive cycle of Epstein-Barr virus. A recombinant ZEBRA protein was synthesized and assessed in enzyme-linked immunosorbent assay (ELISA) for serum IgG response in nasopharyngeal carcinoma (NPC) patients. In 100 NPC serum samples that were positive for IgA to the EBV viral capsid antigen (VCA), 75% had IgG anti-ZEBRA antibodies. In contrast, only 3/83 (3.6%) serum samples from healthy donors and 2/50 (4%) from other cancers were positive for IgG to ZEBRA. Interestingly, in a selected group of 100 NPC sera negative for IgA to VCA, 25% contained IgG anti-ZEBRA antibodies. This suggests that the ELISA for IgG anti-ZEBRA may also identify earlier cases of NPC not detected by the conventional immunofluorescence test for IgA to VCA.
BamHI Z Epstein-Barr病毒复制激活因子（ZEBRA）蛋白参与了爱泼斯坦-巴尔病毒从潜伏期到增殖期的转换。合成了一种重组ZEBRA蛋白，并在酶联免疫吸附测定（ELISA）中评估鼻咽癌（NPC）患者的血清IgG反应。在100份对EBV病毒衣壳抗原（VCA）IgA呈阳性的NPC血清样本中，75%有IgG抗ZEBRA抗体。相比之下，来自健康供体的83份血清样本中只有3份（3.6%）以及来自其他癌症患者的50份血清样本中有2份（4%）对ZEBRA的IgG呈阳性。有趣的是，在一组选定的100份对VCA IgA呈阴性的NPC血清中，25%含有IgG抗ZEBRA抗体。这表明针对IgG抗ZEBRA的ELISA可能也能识别出传统的针对VCA IgA免疫荧光检测未发现的早期NPC病例。
